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Objective To evaluate the utility of prenatal exome sequencing
(ES) for isolated increased nuchal translucency (NT) and to
investigate factors that increase diagnostic yield.
Design Retrospective analysis of data from two prospective cohort
studies.
Setting Fetal medicine centres in the UK and USA.
Population Fetuses with increased NT ≥3.5 mm at 11–14 weeks of
gestation recruited to the Prenatal Assessment of Genomes and
Exomes (PAGE) and Columbia fetal whole exome sequencing
studies (n = 213).
Methods We grouped cases based on (1) the presence of
additional structural abnormalities at presentation in the first
trimester or later in pregnancy, and (2) NT measurement at
presentation. We compared diagnostic rates between groups using
Fisher exact test.
Main outcome measures Detection of diagnostic genetic variants
considered to have caused the observed fetal structural anomaly.
Results Diagnostic variants were detected in 12 (22.2%)
of 54 fetuses presenting with non-isolated increased NT, 12
(32.4%) of 37 fetuses with isolated increased NT in the first
trimester and additional abnormalities later in pregnancy,
and 2 (1.8%) of 111 fetuses with isolated increased NT in
the first trimester and no other abnormalities on subsequent
scans. Diagnostic rate also increased with increasing size
of NT.
Conclusions The diagnostic yield of prenatal ES is low for fetuses
with isolated increased NT but significantly higher where there are
additional structural anomalies. Prenatal ES may not be
appropriate for truly isolated increased NT but timely, careful
ultrasound scanning to identify other anomalies emerging later
can direct testing to focus where there is a higher likelihood of
diagnosis.
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Introduction
An increased nuchal translucency (NT) >3.5 mm detected
at first-trimester ultrasound screening is associated with
fetal chromosomal abnormalities, structural anomalies
(such as congenital heart malformations), and a wide range
of genetic disorders.1,2 Investigation of fetuses with
increased NT typically comprises rapid aneuploidy testing
and chromosomal microarray (CMA) on a fetal DNA sam-
ple obtained through chorionic villus sampling or amnio-
centesis. A chromosomal abnormality will be identified in
approximately 30% of cases3,4 but euploid fetuses with
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increased NT remain at increased risk of adverse outcomes,
proportionally related to the degree of NT enlargement.2–4
In chromosomally normal fetuses with structural anoma-
lies, prenatal exome sequencing (ES) has been shown to
increase the diagnosis of monogenic conditions, with diag-
nostic rates varying widely across different phenotypes.5–8
Two large, prospective studies of unselected fetuses with
any structural abnormality showed that ES provided addi-
tional diagnosis in 8.5% and 10.3% of cases, respectively.5,6
However, in fetuses with multisystem or skeletal abnormal-
ities the diagnostic rate was over 15% whereas in fetuses
with isolated increased NT (≥3.5 mm) the diagnostic rates
were only 3.2% and 2.9%, respectively.5,6 Similar low diag-
nostic rates have also been reported recently for isolated
increased NT,9,10 bringing into question the clinical utility
or cost-effectiveness of prenatal ES in this situation.
With increasing availability of sequencing technology,
decreasing costs and improved speed of bioinformatic ana-
lytical pipelines, rapid fetal ES for prenatal diagnosis is
moving beyond the research arena and has recently been
implemented in the UK National Health Service (NHS)
and in many prenatal diagnosis centres across the USA and
Europe. A clear evidence-base is required to enable the
most efficient use of this new technology. Here we review
the final, extended data sets of the UK Prenatal Assessment
of Genomes and Exomes (PAGE) and USA Columbia
(CUIMC) studies to identify all cases presenting with
increased NT, aiming to further delineate which pregnan-
cies benefit most from prenatal ES. We review natural his-
tories, outcomes and diagnostic variants and explore
factors influencing diagnostic yields to inform further
development of guidelines for the use of prenatal ES in the
presence of increased NT in clinical practice.
Methods
The study cohort comprised fetuses presenting with
increased NT (≥3.5 mm) recruited to the PAGE5 and
CUIMC fetal whole exome sequencing6 studies. The PAGE
study defined increased NT as ≥4.0 mm on first-trimester
ultrasound scanning, measured according to UK NHS Fetal
Anomaly Screening Programme criteria.11 The CUIMC
study defined increased NT as ≥3.5 mm, measured accord-
ing to Nuchal Translucency Quality Review criteria.12 In
the PAGE study there was consecutive recruitment of the
first 100 cases presenting with isolated increased NT, as
recruitment of cases in any specific category was capped at
10% of the total target cohort of 1000 or ˜20% of the run-
ning total.
PAGE study
Here we review 876 fetuses and 1727 matched parental
samples (851 fetus–parent trios and 25 fetus–parent duos),
of which 610 cases (596 trios and 14 duos) have been
reported.5 Study methodology and eligibility criteria were
as previously published5 but in brief, couples undergoing
invasive testing for any ultrasound identified fetal abnor-
mality, including isolated increased NT, were consented for
trio ES where fetal karyotype/CMA were normal. Whole
exome sequencing was performed with analysis targeted to
a virtual panel of 1628 genes associated with developmental
disorders.
CUIMC study
CUIMC recruited a total of 494 fetuses with matched par-
ental samples, of which 234 trios have been reported.6 The
study consented parents with pregnancies complicated by
any fetal abnormality, including isolated increased NT, for
invasive testing or collection of a cord sample after birth.
Untargeted trio whole exome sequencing was performed
when karyotype/CMA was non-causative of the anomaly.
The bioinformatic analysis is described elsewhere.6
Variant interpretation
In both studies, candidate pathogenic variants were curated
and discussed in consensus with relevant clinicians and sci-
entists at a multidisciplinary clinical review panel (CRP).
Only variants classified as ‘pathogenic’ or ‘likely patho-
genic’ according to American College of Medical Genetics
and Genomics guidelines13 and judged likely to cause the
observed structurally abnormal phenotype in the fetus were
considered as positive diagnostic results, validated using
Sanger sequencing and reported to parents after delivery in
the PAGE study or at the time of diagnosis in the CUIMC
study.5,6
Procedures
Interrogation of the study databases identified all fetal cases
presenting at 11–14 weeks of gestation with any of the fol-
lowing terms recorded: ‘Increased nuchal translucency’
(HP:0010880); ‘Fetal cystic hygroma’ (HP:0010878); ‘Cystic
hygroma’ (HP:0000476); ‘Thickened nuchal skin fold’
(HP:0000474), whether in isolation or in combination with
other phenotypes. For the purpose of this analysis, no dis-
tinction was made between increased NT and cystic
hygroma, which can also be described as a septated
increased nuchal translucency, on the basis that practition-
ers documenting the fetal phenotype at the time of recruit-
ment may have used the terms interchangeably and we
sought to capture all relevant cases from the study data-
bases.
To ascertain cases with isolated increased NT at presen-
tation, clinical information was manually reviewed, includ-
ing the phenotypes (Human Phenotype Ontology terms
and free text) recorded in the study databases and ultra-
sound scan reports at presentation. Following manual
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review of this information, any fetus without other struc-
tural anomalies at the point of presentation (including the
absence of so-called ‘soft markers’, such as short femurs or
absent/hypoplastic nasal bone) was classified as ‘initially
isolated increased NT’. Of note, both cohorts included
some cases previously classified and published in other
phenotypic groups as those classifications were originally
based upon the predominant phenotype in the pregnancy
as a whole, whereas here the classifications are based specif-
ically upon the phenotype at initial presentation at 11–
14 weeks of gestation.
For all cases with initially isolated increased NT at pre-
sentation, further ultrasound scan reports and clinical
information from later in pregnancy were reviewed to
ascertain whether the increased NT resolved, remained
isolated, or if additional structural abnormalities were
detected at a later gestation. Cases presenting with fea-
tures consistent with established or evolving fetal hydrops
(generalised oedema, pleural or pericardial effusions,
ascites) were classed as non-isolated increased NT, as fetal
hydrops is a distinct clinical entity with different prognos-
tic implications from isolated increased NT. Pregnancy
outcomes, and postnatal clinical information or post-
mortem findings were ascertained from participating fetal
medicine units.
Outcomes
The primary outcome assessed in both this and the previ-
ously published studies5,6 was the detection of diagnostic
genetic variants considered to have caused the observed
fetal structural anomaly. We reviewed the exome sequence
variants identified in the PAGE and CUIMC studies in this
increased NT cohort and calculated diagnostic rates for
fetuses with: (1) non-isolated increased NT at presentation;
(2) initially isolated increased NT with additional abnor-
malities detected later in pregnancy; and (3) isolated
increased NT that remained isolated or resolved. We also
calculated diagnostic rates according to the measured thick-
ness of NT at presentation.
Statistical analysis
The two-tailed Fisher’s exact test was used to compare rates
of diagnostic genetic variants between sub-groups and Bon-
ferroni correction for multiple testing was applied.
Patient involvement
Design and conduct of the PAGE study was informed by
input from patients and the public through collaboration
with the charity Antenatal Results and Choices. The
CUIMC study was designed and implemented by faculties
of the Department of OBGYN and the Institute for Geno-
mic Medicine. There was no additional patient involvement
for the analysis presented here.
Results
In total, 213 fetuses with increased NT at 11–14 weeks of
gestation were identified; 159 were classified as initially iso-
lated, whereas 54 had additional structural abnormalities or
fetal hydrops at presentation (in the first trimester). Follow-
ing review and classification of candidate variants by the
multidisciplinary CRPs of the studies, 28 (13.1%) of 213
cases had a diagnostic variant identified (Tables 1 and 2).
An additional eight variants (Table S1) were designated
as ‘potentially clinically relevant’ by the PAGE study CRP,
because either there was insufficient evidence to classify the
variant as (likely) pathogenic and/or the prenatal pheno-
type was not specific enough to be unequivocally attributed
to the variant. Six of these were in fetuses with additional
abnormalities and two in fetuses with isolated increased
NT (Table S1). Variants previously published in the PAGE
and CUIMC studies5,6 are indicated in Tables 1, 2 and S1.
Fetuses with increased NT and other anomalies
Diagnostic variants were detected in 12 (22.2%) of 54
fetuses presenting with non-isolated increased NT
(Table 1). Of the 155 pregnancies presenting with initially
isolated increased NT and with follow up to term (Fig. 1),
additional abnormalities were detected in 37 cases (23.9%)
later in pregnancy with diagnostic variants detected in 12
(32.4%). Noonan syndrome accounted for 4/12 (33.3%) of
the diagnoses made (Table 2). A further six fetuses had
variants designated ‘potentially clinically relevant’, of which
2/6 (33.3%) were also in Noonan syndrome genes
(Table S1).
Fetuses with isolated increased NT
In the 111 cases where no other fetal anomalies developed,
and the increased NT either resolved or was not com-
mented on later in pregnancy, a diagnostic variant was
detected in two (1.8%) (Table 2). One was a diagnosis of
maternal chromosome 15 uniparental disomy, not detected
on prenatal CMA, in a fetus presenting with an NT of
4.8 mm at 13 weeks of gestation who was born at term,
small for gestational age but with no apparent congenital
abnormalities observed on clinical examination (Table S2).
The second was a fetus presenting with isolated NT of
3.5 mm and found to have a de novo frameshift variant in
the gene RERE. This fetus also had no apparent congenital
abnormalities at birth, but at 8 months of age had clinical
features consistent with RERE-related disease, at which
point the prenatally detected variant was reclassified as
pathogenic by the study multidisciplinary team. Two fur-
ther cases had ‘potentially clinically relevant’ variants
(Table S1). One, with a variant in KMT2A, had a sacral
dimple at birth but no other problems were noted on fol-
low up to 2 years of age to allow a diagnosis of
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Wiedemann–Steiner syndrome to be made. The second had
a KMT2D variant and although there were no problems
detected on clinical examination at birth, examination at
18 months revealed fetal finger pads, arched eyebrows and
a sacral dimple, which allowed confirmation of a diagnosis
of Kabuki syndrome.
Fetuses with no follow up
In seven cases, the pregnancies ended soon after the initial
presentation with no further scans performed. Diagnostic
variants were detected in two (28.6%) of these cases
(Table 2). Post-mortem examination confirmed findings
compatible with Cornelia de Lange syndrome in the fetus
with a de novo pathogenic NIPBL truncating variant. In the
other, with a de novo likely pathogenic PTPN11 variant,
post-mortem confirmed the presence of a cystic hygroma.
Four further cases, with no diagnostic variants identified,
were lost to follow up and scan reports from later in the
pregnancies were not available for review. These 11 cases are
excluded from further analysis of diagnostic rates.
Sub-analysis according to the presence of additional
structural abnormalities compared with pregnancies with
Table 1. Diagnostic variants identified after trio ES and review by PAGE/CUIMC study CRP in fetuses initially presenting with non-isolated

















PP3174 4.1 Rhizomelia N/A (IUD) TRIP11 c.757C>T p.(Arg253*) [Hom] LP
PP1780 8.6 Encephalocele; hypoplastic thorax; TR; polycystic
dysplastic kidneys; polydactyly; bilateral talipes;
short long bones
As at presentation TCTN2 c.1506-2A>G [Hom]** P




SOS1 pathogenic variant [Pat]
additionally detected on a
postnatal RASopathy panel
P





PP4147 5.0 Cystic hygroma; oedema; polydactyly; bright
kidneys; encephalocele
N/A (ToP) TCTN3 c.628-13_643del (splice
variant) [Hom]
P
PP3324 6.1 Septated cystic hygroma; hydrops N/A (ToP) BRAF c.1782T>G p.(Asp594Glu) [De
novo Het]
LP






PP3732 19.0 Cystic hygroma; fixed flexed extremities; no
stomach or bladder seen
N/A (ToP) RYR1 420bp deletion encompassing
exon 29 [Hom]
LP





PP4393 N/S Cystic hygroma; hydrops; fixed flexed extremities;
fetal akinesia sequence





Fetal0183 3.5 Micromelia; micrognathia; talipes; ambiguous
genitalia
N/A (ToP) COL2A1 c.1358G>T p.(Gly453Val)
[De novo Het]**
P
ACMG, American College of Medical Genetics and Genomics; CCAM, congenital cystic adenomatous malformation; Hemi, hemizygous; Het,
heterozygous; Hom, homozygous; IUD, in utero death; LP, likely pathogenic; Mat, maternal; N/A, not applicable; N/S, not specified; P,
pathogenic; Pat, paternal; ToP, termination of pregnancy; TR, tricuspid regurgitation; VM, ventriculomegaly; VSD, ventricular septal defect.
**Variants previously published.
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‘truly’ isolated increased NT showed a significant increase
in the diagnostic rate both where additional abnormalities
were seen at presentation (1.8% versus 22.2% P < 0.001),
and where additional abnormalities developed later (1.8%
versus 32.4% P < 0.001). There was no statistically signifi-
cant difference in the frequency of diagnostic variants
between fetuses with additional abnormalities at presenta-
tion and those developing additional abnormalities at a
later gestation (22.2% versus 32.4% P = 0.336).
Review of sequencing results in relation to the size of
isolated increased NT at presentation (Table 3) showed
that diagnostic rate increased with increasing size of NT,






Findings at later scans Variant(s) ACMG
class
Fetuses with initially isolated increased NT, then other anomalies detected later








PP0503 4.5 None AVSD PTPN11 c.922A>G p.(Asn308Asp)
[Mat]**
P
PP0692 6.0 None Short limbs, polyhydramnios RAF1 c.786T>G p.(Asn262Lys) [De
novo Het]
LP
PP1864 7.4 None Hypoplastic left heart syndrome with DORV,
TGA, PA
KMT2D c.673+1G>A [De novo
Het]**
LP




PP1462 8.9 None Short femurs; cystic dilatation of lymphatics from
neck to upper chest; bilateral RPD
BRAF c.770A>G p.(Gln257Arg) [De
novo Het]**
P
PP1807 4.7 None Hypoplastic right heart; VSD MID1 c.1102C>T p.(Arg368*) [De
novo Hemi]**
P
Fetal0116 N/S None Hydrocephalus; hyperflexed feet








Fetal0222 5.2 None Pleural effusion; ascites SOS1 c.1132A>G p.(Thr378Ala)
[Pat]**
P
Fetal0307 4.7 None Shones complex NR2F2 c.1091delT
p.(Leu364Cysfs*15) [De novo Het]
P





Fetuses with initially isolated increased NT which remained isolated or resolved later in pregnancy
PP0602 4.8 None None Chr15 UPD [Mat]** N/A
Fetal0045 3.5 None None RERE c.248dupA p.(Ser84Valfs*4)
[De novo Het]**
LP
Fetuses presenting with initially isolated increased NT where later pregnancy follow up was not possible
PP3321 9.9 None N/A (ToP) PTPN11 c.214G>A p.(Ala72Thr) [De
novo Het]
LP
PP2039 6.2 None N/A (IUD) NIPBL c.1435C>T p.(Arg479*) [De
novo Het]**
P
ACMG, American College of Medical Genetics and Genomics; ASD, atrial septal defect; AVSD, atrioventricular septal defect; DORV, double outlet
right ventricle; Hemi, hemizygous; Het, heterozygous; IUD, in utero death; LP, likely pathogenic; Mat, maternal; N/A, not applicable; N/S, not
specified; P, pathogenic; PA, pulmonary atresia; Pat, paternal; RPD, renal pelvis dilatation; TGA, transposition of great arteries; ToP, termination of
pregnancy; UPD, uniparental disomy; VSD, ventricular septal defect.
**Variants previously published.
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from 1.6% (1/63 cases) where NT was between 3.5 and




In this cohort of pregnancies enrolled in the first trimester
with an increased NT of at least 3.5 mm, we observed a
relatively low rate of diagnostic variants (1.8%) from pre-
natal ES for isolated increased NTs that remained isolated
throughout the pregnancy. However, there was an
increased diagnostic rate where fetuses had additional
structural anomalies or hydrops, either at presentation
(22.2%) or developing later in pregnancy (32.4%) We also
observed significantly higher diagnostic rates where the size
of the isolated increased NT was larger at presentation.
It is of note that in the studies we describe there were
some likely pathogenic/pathogenic variants that did not
explain the fetal phenotype. In line with the study proto-
cols, these variants were not initially reported to the
parents. However, postnatal follow up in two cases, a fetus
with an RERE variant and one with a KMT2D variant,
revealed an evolving phenotype compatible with these vari-
ants and results were reported to parents. These cases high-
light one of the limitations of fetal phenotyping, and how
with prenatal sequencing we are expanding our
Figure 1. Natural history of pregnancies presenting with increased NT below 14 weeks of gestation.
Table 3. Number of diagnostic variants identified by trio ES in
relation to size of isolated NT at presentation
NT (mm) Number of cases Diagnostic variants
detected (%)
3.5–4.4 63 1 (1.6)
4.5–5.4 42 6 (14.2)
5.5–6.4 22 2 (9.1)
6.5–7.4 11 2 (18.2)
≥7.5 14 4 (28.6)
Not specified 7 1 (14.3)
Total 159 16 (10.1)
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understanding of fetal phenotype–genotype relationships
previously only recognised postnatally. Documenting this
growing knowledge is essential for accurate prenatal inter-
pretation and complete reproductive genetic counselling in
future cases.
It is also notable that this cohort includes three diagnoses
of Noonan syndrome where causative variants were inherited
from undiagnosed affected parents (PP2567, PP0503,
fetal0222). In two cases there was a history of previous preg-
nancy loss with relevant phenotypes (large cystic hygroma
and fetal hydrops, respectively), and in two cases the affected
parent had unrecognised clinical features of Noonan syn-
drome. These cases highlight the need for careful review of
family and past obstetric history, as well as careful, expert
parental examination when considering the underlying aeti-
ology of increased NT to guide molecular testing, particularly
where genes exhibit variable penetrance or expression.
Strengths and limitations
A strength of this study is its relatively large sample size,
drawn from the two largest published prenatal ES cohorts to
date. Further, the prospectively collected, unselected nature
of the cohort, and the detailed approach to examining the
natural histories of the pregnancies presenting with isolated
increased NT, make this study relevant to clinical practice
where rapid ES may be considered in an ongoing pregnancy.
Despite the large size of the PAGE and CUIMC studies,
the number of fetuses recruited with (apparently) isolated
increased NT is not as high as might be expected because
the PAGE study ‘capped’ recruitment of fetuses in any one
category at ˜20% of the ongoing total.5 Ultimately, it will
be beneficial to study much larger cohorts to inform coun-
selling and guide the future use of ES for this group.
Furthermore, varied interpretations of ‘isolated’ increased
NT (e.g. isolated at presentation versus isolated throughout
the entire pregnancy, and whether or not ‘soft markers’ of
genetic abnormality are classed as additional abnormalities)
limit comparison of results between studies. A further limi-
tation of prenatal ES for the investigation of isolated
increased NT is the difficulty in interpreting genetic vari-
ants in the absence of specific fetal phenotypes, exacerbated
by a dearth of publically available data regarding the com-
plete spectrum of Mendelian disease in the fetal period.
Interpretation
Other recent small studies of prenatal trio ES have also
observed relatively low diagnostic rates of 0–3% for isolated
increased NT,9,10 particularly when specifically reporting
cases without structural abnormalities developing later in
pregnancy.14 These low numbers of molecular diagnoses
from prenatal ES are consistent with an existing body of
evidence indicating that once chromosomal abnormalities
are excluded, if detailed follow-up scanning demonstrates
resolution of the increased NT and the absence of any
major abnormalities, then the chance of delivering a
healthy infant with no major abnormalities is >95%.1–3
Our observation that diagnoses from prenatal ES increased
with enlarging size of NT at presentation is also in keeping
with the known association between significant underlying
pathogenicity and increasing NT thickness.1
In contrast to our findings, a recent smaller retrospec-
tively collected cohort study reported by Choy et al. using
prenatal whole genome sequencing reports a diagnostic
yield of 17.2% (5/29 cases) among fetuses with isolated
increased NT and normal CMA, and found no significant
difference between isolated and non-isolated increased NT
groups.15 The pathogenic variants reported comprised one
case of mosaic Turner syndrome (45,X) not detected on
CMA, and four variants in the genes ARMC4, ANKRD11,
GATA4 and NSD1, all of which would have been amenable
to detection by whole exome sequencing in the PAGE and
CUIMC studies. Differences in the approach to reporting
variants may contribute to the difference in diagnostic rates
between this and our studies. In the study by Choy et al.,
findings were not reported back to families, whereas diag-
nostic findings from the PAGE and CUIMC studies were
confirmed in a clinical laboratory and reported to families
after the end of the pregnancy.15 The CRPs of these studies
took a stringent approach to reporting only variants classi-
fied (likely) pathogenic and considered causative of the
fetal phenotype. With a non-specific fetal phenotype such
as isolated increased NT, it may be challenging to make a
definitive genotype–phenotype correlation as well as there
being some subjectivity in reporting decisions. This is espe-
cially true for novel variants as reported by Choy et al.15
This highlights an important point about the need for clear
(international) consensus guidelines for reporting variants
detected by prenatal ES or whole-genome sequencing in
clinical practice, where results will be largely returned dur-
ing an ongoing pregnancy and will have implications for
counselling and management in that pregnancy.
Conclusion
These findings have clinical implications for offering prena-
tal ES in obstetric practice, where testing should aim to
maximise benefit to patients without unduly increasing
parental anxiety, and are particularly pertinent in view of
the recent introduction of rapid fetal exome sequencing in
the English NHS.16 Trio ES currently remains relatively
costly and time consuming and this inevitably plays a role
in determining how prenatal ES can be offered. In England,
for example, limited numbers of prenatal ES are funded, so
cases must fulfil specific eligibility criteria16 such that only
those with a higher likelihood of a monogenic disorder are
tested. Criteria for offering prenatal ES will vary across
7ª 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Exome sequencing for increased nuchal translucency
different healthcare systems but all guidelines must take
into account both clinical utility and cost-effectiveness to
direct finite resources appropriately. Until the costs of trio
ES fall and testing capacity expands, it is unlikely in a pub-
licly funded healthcare setting that all pregnancies with an
increased NT can be offered ES. As diagnostic yield for
completely isolated increased NT is low, a suggested strat-
egy is to offer prenatal ES for increased NT only when
additional fetal structural abnormalities are present and
then offer early detailed scanning to detect emerging
anomalies for those with apparently isolated increased NT.
Such an approach would integrate well into existing care
pathways as many providers already have established proto-
cols for following up isolated increased NT detected at
first-trimester scanning with detailed anomaly scanning
and/or fetal echocardiography at 16–18 weeks of gestation.
Detecting additional abnormalities before the routine
second-trimester anomaly scan could facilitate completion
of ES in a timely fashion. As many of these pregnancies
with an increased NT in the first trimester will have under-
gone chorionic villus sampling for detection of aneuploidy
and copy number variations, DNA can be saved at the time
of the initial diagnostic testing, which can subsequently be
used for ES if second-trimester ultrasound reveals an
emerging phenotype.
In our combined cohort (from two countries), such a
strategy would have avoided 116 negative ESs but missed
two diagnoses – chromosome 15 uniparental disomy (ma-
ternal) in a fetus with isolated increased NT of 4.8 mm at
13 weeks of gestation and normal scans thereafter, and a
RERE-related developmental disorder in a fetus with iso-
lated increased NT of 3.5 mm and normal scans thereafter.
A further consideration is whether this stepwise strategy
would be acceptable to patients, given that detection of
increased NT in the first trimester induces anxiety and any
wait for further investigations may be stressful. Detailed
investigation of this question is beyond the scope of the
current study but further research to explore patient per-
spectives is underway.17
As reported by others,1 the risk of underlying pathology
increases with increasing NT size. In our cohort, 4/14
(28.6%) of cases with an isolated NT ≥7.5 mm in the first
trimester had a diagnostic pathogenic variant. The numbers
are small and further study is required, but a policy of
offering ES for isolated NT of this size may be worth con-
sidering.
Where panel testing for RASopathies is available prena-
tally, this could provide an alternative option for investigat-
ing very large isolated increased NT.18 The case of Kabuki
syndrome described above (PP0722), together with other
published evidence,6,7,15 demonstrates that Kabuki syn-
drome can present prenatally with increased NT, so limited
analysis for this condition as well as Noonan spectrum
disease may be worthy of consideration in the future where
significant and persistent isolated increased NT is identi-
fied. A potential alternative strategy here to limit costs may
be to sequence the fetus alone and investigate parents only
where a relevant variant is found in the fetus. Should a
limited panel approach be offered, clinicians must provide
clear counselling to parents regarding the benefits and limi-
tations of analysing only a small gene set.
Our findings further highlight the significant challenges
of variant interpretation in the prenatal setting when the
fetal phenotype is incomplete or non-specific. In the PAGE
study results were analysed and returned after the end of
the pregnancy but in clinical practice, where ES results will
be returned rapidly in an ongoing pregnancy we need
guidelines on reporting when the prenatal phenotype is
incomplete and the phenotype–genotype correlation is
uncertain. As experience with prenatal ES increases and the
variations in prenatal phenotypes are further recognised,
interpretation and reporting will become clearer.
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